Answers are grounded in this paper and cite their sources.
The occurrence or the worsening of cutaneous T-cell lymphoma (CTCL) during or after a treatment with dupilumab has recently been reported in a limited number of patients including a small series of 7 patients, of whom 4 had been previously diagnosed with atopic dermatitis (AD).1 We hereby describe a previously unreported observation of systemic CD30+ lymphoproliferation occurring during treatment with dupilumab, adding to the literature of new-onset cutaneous lymphomas associated with dupilumab therapy.
No takes yet. Share an insight, caveat, or question.
Du‐Thanh et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: